Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. SRPT Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Sarepta Therapeutics (SRPT)

Market Price (9/16/2025): $17.48 | Market Cap: $1.7 Bil
Sector: Health Care | Industry: Biotechnology

Sarepta Therapeutics (SRPT)

Market Price (9/16/2025): $17.48
Market Cap: $1.7 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 65%		 Weak multi-year price returns
2Y Excs Rtn is -133%, 3Y Excs Rtn is -150%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -0.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 0.0%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -93%		  Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -18%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.9%
3   Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21%
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 65%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -93%
2 Weak multi-year price returns
2Y Excs Rtn is -133%, 3Y Excs Rtn is -150%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -0.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 0.0%
4 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -18%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.9%
6 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21%

Market Valuation

 9/16/252024202320222021
Share Price CYE$17.48$121.59$96.43$129.58$90.05
Market Cap CYE ($ Bil)1.717.910.011.47.7
Total Debt ($ Bil)1.41.31.41.61.2
Total Cash ($ Bil)0.81.41.72.02.1
Enterprise Value ($ Bil)2.319.211.413.08.9
Valuation Ratios     
P/S TTM0.76.97.212.210.4
P/EBIT TTM-342.147.0-17.9-17.8-20.6
P/E TTM-29.655.8-16.6-16.1-17.5
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.9-1.6-1.5-1.4-2.9
 9/16/2520242023
Share Price CYE$17.48$121.59$96.43
Market Cap CYE ($ Bil)1.717.910.0
Total Debt ($ Bil)1.41.31.4
Total Cash ($ Bil)0.81.41.7
Enterprise Value ($ Bil)2.319.211.4
Valuation Ratios   
P/S TTM0.76.97.2
P/EBIT TTM-342.147.0-17.9
P/E TTM-29.655.8-16.6
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.9-1.6-1.5

Market Cap Chart

Business Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
SRPT Return32%-47%44%-26%26%-86%-87%
Peers Return98%29%4%-11%-17%41%177%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ALNY, MRNA, IONS, ARWR, ABBV. See SRPT Returns vs. Peers.
[3] 2025 data is for the year up to 9/15/2025 (YTD)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1SRPT Stock in Focus: Does It Outshine the Peer Group?  
2SRPT Dropped 14% In A Month. Have You Fully Evaluated The Risk?Return 
3SRPT Dip Buy Analysis  
4Sarepta Therapeutics Earnings Notes  
5Sarepta Therapeutics Total Shareholder Return (TSR): 26.1% in 2024 and 10.5% 3-yr compounded annual returns (above peer average)  
6Sarepta Therapeutics (SRPT) Operating Cash Flow ComparisonFinancials 
7Sarepta Therapeutics (SRPT) Net Income ComparisonFinancials 
8Sarepta Therapeutics (SRPT) Operating Income ComparisonFinancials 
9Sarepta Therapeutics (SRPT) Revenue ComparisonFinancials 
10Sarepta Therapeutics vs. S&P500 CorrelationCorrelation 
11ARTICLES  
12Market Movers | Winners: TLRY, VTLE, UP | Losers: KDP, SRPT, FRPT August 25th, 2025
13SRPT Stock in Focus: Does It Outshine the Peer Group? August 20th, 2025
14Market Movers | Winners: SRPT, LYEL, SMCI | Losers: ALB, ULH, GERN July 29th, 2025
15Stocks Trading At 52-Week Low July 26th, 2025
16Stocks Trading At 52-Week Low July 24th, 2025
Title
0DASHBOARDS
1Market Movers | Winners: TLRY, VTLE, UP | Losers: KDP, SRPT, FRPT
2SRPT Stock in Focus: Does It Outshine the Peer Group?
3Market Movers | Winners: SRPT, LYEL, SMCI | Losers: ALB, ULH, GERN
4Stocks Trading At 52-Week Low
5Stocks Trading At 52-Week Low
6ARTICLES
7SRPT Stock in Focus: Does It Outshine the Peer Group?
8SRPT Dropped 14% In A Month. Have You Fully Evaluated The Risk?
9SRPT Dip Buy Analysis
10Sarepta Therapeutics Earnings Notes
11Sarepta Therapeutics Total Shareholder Return (TSR): 26.1% in 2024 and 10.5% 3-yr compounded annual returns (above peer average)
12Sarepta Therapeutics (SRPT) Operating Cash Flow Comparison
13Sarepta Therapeutics (SRPT) Net Income Comparison
14Sarepta Therapeutics (SRPT) Operating Income Comparison
15Sarepta Therapeutics (SRPT) Revenue Comparison
16Sarepta Therapeutics vs. S&P500 Correlation

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO7309.3% 
3CHSNChanson International5551.3%-99.3%
4LNZALanzaTech Global5145.9%-85.7%
5QMMMQMMM2490.3%5505.5%
6NXTTNext Technology2167.7%1080.3%
7VTAKCatheter Precision1543.9%-70.5%
8CURXCuranex Pharmaceuticals1282.0%1282.0%
9VCIGVCI Global1278.3%-66.8%
10OCTOEightco800.6%562.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-93.3%-95.1%
2ELPWElong Power-92.4%-76.5%
3STFSStar Fashion Culture-92.1%-97.9%
4ETSElite Express-92.0%-92.0%
5NAKAKindly MD-91.7% 
6BINIBollinger Innovations-90.5%-100.0%
7FLYEFly-E-89.8%-81.2%
8JEM707 Cayman-89.8%-98.3%
9NUTRNusaTrip-86.7%-86.7%
10CUPRCuprina-84.9% 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NXTTNext Technology18985.5%1080.3%
2BDSXBiodesix1658.4%-75.2%
3VCIGVCI Global1460.0%-66.8%
4CLSDClearside Biomedical1075.2%-72.3%
5SDOTSadot806.7%-78.2%
6WLDSWearable Devices539.8%-24.4%
7QMMMQMMM536.6%5505.5%
8ATCHAtlasClear382.9%-89.7%
9OPIOffice Properties Income Trust274.5%-8.3%
10CWDCaliberCos246.5%-46.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1DGNXDiginex-83.7% 
2ATYRaTyr Pharma-81.4%-72.0%
3LGCLLucas GC-73.2%-78.3%
4NAKAKindly MD-72.8% 
5OCTOEightco-67.8%562.1%
6YYGHYY-67.0%-78.2%
7SNTGSentage-58.1%57.5%
8REXREX American Resources-50.7%-26.7%
9BINIBollinger Innovations-49.2%-100.0%
10SLXNSilexion Therapeutics-49.2%-88.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Sarepta Therapeutics

Financials

SRPTALNYMRNAIONSARWRABBVMedian
NameSarepta .Alnylam .Moderna Ionis Ph.Arrowhea.AbbVie  
Mkt Price17.47461.1423.8861.1028.67217.6144.89
Mkt Cap1.759.89.39.74.0384.79.5
Rev LTM2,4822,3483,05571757358,3282,415
Op Inc LTM-1-115-3,273-472-10813,695-112
FCF LTM-454-75-3,500-563-1818,239-265
FCF 3Y Avg-505-184-2,744-438-29820,273-368
CFO LTM-301-45-2,697-5022219,283-173
CFO 3Y Avg-395-131-2,055-401-17521,154-285

Growth & Margins

SRPTALNYMRNAIONSARWRABBVMedian
NameSarepta .Alnylam .Moderna Ionis Ph.Arrowhea.AbbVie  
Rev Chg LTM64.9%17.2%-38.8%-7.6%2,816.2%6.1%11.6%
Rev Chg 3Y Avg45.0%40.8%-48.0%-1.4%908.8%0.6%20.7%
Rev Chg Q68.4%20.2%-38.0%10.1%-6.6%10.1%
QoQ Delta Rev Chg LTM11.1%4.4%-2.7%1.7%5.1%1.7%3.1%
Op Mgn LTM-0.0%-4.9%-107.1%-65.9%-18.8%23.5%-11.9%
Op Mgn 3Y Avg-16.1%-27.5%-65.1%-65.7%-958.1%27.2%-46.3%
QoQ Delta Op Mgn LTM5.2%3.0%11.7%1.5%2.9%1.0%2.9%
CFO/Rev LTM-12.1%-1.9%-88.3%-70.0%3.8%33.1%-7.0%
CFO/Rev 3Y Avg-29.1%-13.1%-51.8%-59.0%-620.8%37.5%-40.4%
FCF/Rev LTM-18.3%-3.2%-114.6%-78.5%-3.1%31.3%-10.8%
FCF/Rev 3Y Avg-35.5%-16.6%-67.2%-64.4%-949.2%36.0%-50.0%

Valuation

SRPTALNYMRNAIONSARWRABBVMedian
NameSarepta .Alnylam .Moderna Ionis Ph.Arrowhea.AbbVie  
Mkt Cap1.759.89.39.74.0384.79.5
P/S0.725.53.013.57.06.66.8
P/EBIT-342.0-284.6-3.2-25.7-53.165.3-39.4
P/E-29.5-221.7-3.2-21.2-26.9102.2-24.0
P/CFO-5.7-1,325.6-3.4-19.3182.520.0-4.6
Total Yield-3.4%-0.5%-31.3%-4.7%-3.7%3.9%-3.6%
Dividend Yield0.0%0.0%0.0%0.0%0.0%2.9%0.0%
FCF Yield 3Y Avg-12.0%-0.8%-14.3%-7.0%-8.8%7.3%-7.9%
D/E0.80.00.10.10.10.20.1
Net D/E0.3-0.0-0.5-0.1-0.10.2-0.0

Returns

SRPTALNYMRNAIONSARWRABBVMedian
NameSarepta .Alnylam .Moderna Ionis Ph.Arrowhea.AbbVie  
1M Rtn-19.9%2.7%-14.8%39.6%39.8%5.3%4.0%
3M Rtn-16.6%49.3%-8.2%73.4%82.6%15.0%32.2%
6M Rtn-82.8%82.2%-31.2%78.1%83.8%3.3%40.7%
12M Rtn-86.0%73.8%-65.0%44.8%33.4%16.1%24.7%
3Y Rtn-84.4%116.5%-82.7%31.9%-17.1%69.1%7.4%
1M Excs Rtn-16.2%1.9%-12.8%40.3%50.4%4.0%3.0%
3M Excs Rtn-62.4%39.0%-21.1%61.0%71.5%4.2%21.6%
6M Excs Rtn-99.3%73.4%-48.3%68.1%69.3%-12.7%27.7%
12M Excs Rtn-105.5%57.0%-89.1%24.6%17.8%-3.3%7.3%
3Y Excs Rtn-150.5%38.6%-148.2%-27.1%-91.9%8.2%-59.5%

Comparison Analyses

Title
0Sarepta Therapeutics vs. Arrowhead Research: With Return Forecast Of 103%, Arrowhead Research Is A Better Bet
1With 85% Gains On The Table, SRPT May Outshine ALNY
2SRPT Looks Stronger Than IONS With 85% Return Potential
3Sarepta Therapeutics vs. DexCom: With Return Forecast Of 78%, DexCom Is A Better Bet
4Sarepta Therapeutics vs. Floor & Decor Holdings: With Return Forecast Of 72%-76%, Both Seem Like Good Bets
5Sarepta Therapeutics vs. Capri Holdings Limited: With Return Forecast Of 72%, Sarepta Therapeutics Is A Better Bet
6Sarepta Therapeutics vs. Royal Gold: Similar Revenue, But Sarepta Therapeutics Is A Better Bet
7Sarepta Therapeutics vs. Coupa Software: Similar Revenue, But Coupa Software Is A Better Bet
8Sarepta Therapeutics vs. Aspen Technology: Similar Revenue, But Sarepta Therapeutics Is A Better Bet
9Sarepta Therapeutics vs. Under Armour: Similar Market Cap, But Sarepta Therapeutics Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/6/20255/6/20252/28/202511/6/20248/7/20245/1/20242/28/202411/1/20238/2/20235/2/20232/28/202311/2/2022
Key Financials Quarterly            
Total Revenue611745658467363413397332261254258230
Ebitda170-36918749275457-171-495-84-231
Operating Income116-30016222-13525-21-134-138-107-131
Net Income197-4481593463646-41-24-517-109-258
EPS2.01-4.601.650.350.070.380.76-0.46-0.27-5.86-1.24-2.94
Key Financials TTM            
Total Revenue TTM2,4822,2331,9021,6401,5051,4031,2431,1051,003976933876
Ebitda TTM36-10731718712196-454-595-809-1,012-595-606
Operating Income TTM-1-1172188138-95-268-399-510-587-536-535
Net Income TTM-58-2482351224717-536-691-908-1,115-703-716
Growth Rates Quarterly            
Total Revenue Growth68.4%80.2%65.9%40.8%38.9%63.1%53.5%44.1%11.9%20.2%28.3%21.6%
EBITDA Growth525.6%-778.9%227.6%386.4%1795.7%111.0%167.8%92.6%100.7%-537.7%12.2%-978.5%
Operating Income Growth16587.4%-960.6%556.6%206.5%99.5%125.3%123.0%84.1%36.8%-58.9%-1.0%-281.2%
Net Income Growth2947.9%-1339.0%248.4%182.1%127.0%107.0%141.8%84.1%89.7%-392.0%10.4%-435.3%
Margins Quarterly            
EBITDA Margin27.8%-49.5%28.4%10.4%7.5%13.1%14.4%-5.1%0.5%-195.3%-32.5%-100.3%
Operating Income Margin18.9%-40.3%24.6%4.8%-0.2%8.4%6.2%-6.3%-51.1%-54.5%-41.3%-57.0%
Net Income Margin32.2%-60.1%24.2%7.2%1.8%8.7%11.5%-12.3%-9.2%-203.8%-42.3%-111.9%
Cash & Debt            
Total Cash8005231,3551,1981,4601,3911,6761,7341,8611,8821,9892,072
Total Debt1,3541,3441,3431,3981,3701,3791,3971,3721,3651,2881,6171,578
Net Debt / (Cash)554821-12199-91-11-279-362-496-594-372-494
Cash Flows Quarterly            
FCF from Operations261-58392-7115-242-55-115-122-209-92-65
Cash Flows TTM            
FCF from Operations TTM-301-547-206-352-396-534-501-539-489-434-325-262
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC7.3%-18.1%10.5%1.5%-0.0%2.3%2.0%-1.7%-11.4%-12.2%-10.9%-14.1%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-0.0%-1.8%3.4%1.3%0.5%-0.9%-5.3%-8.2%-10.9%-12.9%-13.7%-14.3%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Phosphorodiamidate morpholino oligomer (PMO) Products945844   
ELEVIDYS2000   
Collaboration and Other98898984 
AMONDYS 45  900 
EXONDYS 51  454422 
VYONDYS 53  6934 
Products, net    381
Total1,243933702540381


Price Behavior

SRPT Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta2.702.960.691.331.240.92
Up Beta2.123.571.041.411.300.99
Down Beta4.114.223.201.271.341.50
Up Capture313%259%-166%-28%-5%5%
Bmk +ve Days10223571142415
Stock +ve Days10202754109354
Down Capture200%326%270%193%148%100%
Bmk -ve Days11192754106334
Stock -ve Days11213571139394

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity20,310,502
Short Interest: % Change Since 815202511.3%
Average Daily Volume9,948,810
Days-to-Cover Short Interest2.04
Basic Shares Quantity98,005,000
Short % of Basic Shares20.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/16/202519.5%-27.5%10.4%
1/13/20250.3%-1.4%-7.3%
1/8/202416.7%12.5%22.8%
1/9/20231.4%10.6%3.3%
1/10/2022-10.9%-16.8%-11.8%
10/15/2021-3.5%-4.7%-0.4%
1/11/20219.1%9.8%13.2%
1/13/2020-3.4%-0.9%-3.9%
SUMMARY STATS   
# Positive534
# Negative354
Median Positive9.1%10.6%11.8%
Median Negative-3.5%-4.7%-5.6%
Max Positive19.5%12.5%22.8%
Max Negative-10.9%-27.5%-11.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/30/2025
3312025506202510-Q 3/31/2025
12312024228202510-K 12/31/2024
93020241106202410-Q 9/30/2024
6302024807202410-Q 6/30/2024
3312024501202410-Q 3/31/2024
12312023228202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023802202310-Q 6/30/2023
3312023502202310-Q 3/31/2023
12312022228202310-K 12/31/2022
93020221102202210-Q 9/30/2022
6302022802202210-Q 6/30/2022
3312022504202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Boor Kathryn Jean 12062024Sell125.551,636205,400738,234Form
1Estepan Ian MichaelChief Financial Officer9032024Sell137.365,985822,1004,662,823Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.